Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Salesforce Inc (CRM) vs Dolby Laboratories, Inc. (DLB) Price & Performance

Salesforce IncTrade
Dolby Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Salesforce Inc vs Dolby Laboratories, Inc. — how do they compare? Salesforce Inc trades at $228.9 (market cap $187.48B), while Dolby Laboratories, Inc. trades at $58.9 (market cap $5.47B). The key difference: Salesforce Inc is far larger — about 34.3× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.46%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Dolby Laboratories, Inc. for 98 Days on average.

CRMDLB
Market Cap
$187.48B$5.47B
Volume
6,155,8221,058,284
Sector
TechnologyTechnology
52-Week High
$266.23$70.09
52-Week Low
$150.12$48.51
Typical Hold Time
89 Days98 Days
Enterprise Value
$217.82B$4.85B
Dividend Yield
0.77%2.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Salesforce Inc

Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected), robust profitability (77.28% gross margin, 21.99% net margin), and healthy cash flow generation ($13.09B operating cash flow in 2025). Technical indicators remain bearish with current price near pivot point support at $224.

Outlook remains positive long-term given Salesforce's dominant market position, AI monetization growth (Agentforce ARR up 107% quarterly), and analyst consensus target of $271.91 (21% upside). Near-term risks include software sector volatility and competitive AI threats, but strong fundamentals support recovery potential from current discounted valuation levels.

Dolby Laboratories, Inc.

Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals. The company maintains strong profitability with 87.61% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten. Cash flow improved significantly in 2025 with $472M operating cash flow.

DLB presents a mixed outlook with strong fundamentals but technical weakness. The 47% upside to $90.33 consensus target offers potential, though near-term execution risks and licensing volatility remain concerns. Revenue stability around $1.3B and premium valuation metrics require continued innovation execution to justify current multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRM
97% Buy3% Sell
Avg holding period · 89 Days
DLB

No sentiment data available yet.

Top news

Latest headlines on both assets

About Salesforce Inc

Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.

Read more on CRM →

About Dolby Laboratories, Inc.

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.

Read more on DLB →